These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15026036)

  • 21. Discovery and SAR of 4-amino-2-biarylbutylurea MCH 1 receptor antagonists through solid-phase parallel synthesis.
    Guo T; Hunter RC; Gu H; Rokosz LL; Stauffer TM; Hobbs DW
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3691-5. PubMed ID: 15953726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).
    Ghosh S; Elder A; Guo J; Mani U; Patane M; Carson K; Ye Q; Bennett R; Chi S; Jenkins T; Guan B; Kolbeck R; Smith S; Zhang C; LaRosa G; Jaffee B; Yang H; Eddy P; Lu C; Uttamsingh V; Horlick R; Harriman G; Flynn D
    J Med Chem; 2006 May; 49(9):2669-72. PubMed ID: 16640325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening of thiourea derivatives and carbonyl-2-aminothiazole derivatives for potential CCR4 antagonists using capillary zone electrophoresis.
    Zhang S; Qi H; Yakufu P; Zhao F; Ling X; Xiao J; Wang Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jan; 879(1):75-82. PubMed ID: 21144808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series.
    Moree WJ; Kataoka K; Ramirez-Weinhouse MM; Shiota T; Imai M; Tsutsumi T; Sudo M; Endo N; Muroga Y; Hada T; Fanning D; Saunders J; Kato Y; Myers PL; Tarby CM
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1869-73. PubMed ID: 18313297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine.
    Richardson SK; Newton SB; Bach TL; Budgin JB; Benoit BM; Lin JH; Yoon JS; Wysocka M; Abrams CS; Rook AH
    Am J Hematol; 2007 Sep; 82(9):792-7. PubMed ID: 17546636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of 3-piperidinyl-1-cyclopentanecarboxamide as a novel scaffold for highly potent CC chemokine receptor 2 antagonists.
    Yang L; Butora G; Jiao RX; Pasternak A; Zhou C; Parsons WH; Mills SG; Vicario PP; Ayala JM; Cascieri MA; MacCoss M
    J Med Chem; 2007 May; 50(11):2609-11. PubMed ID: 17461566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3-Amino-1-alkyl-cyclopentane carboxamides as small molecule antagonists of the human and murine CC chemokine receptor 2.
    Butora G; Jiao R; Parsons WH; Vicario PP; Jin H; Ayala JM; Cascieri MA; Yang L
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3636-41. PubMed ID: 17482462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.
    De Lucca GV; Kim UT; Vargo BJ; Duncia JV; Santella JB; Gardner DS; Zheng C; Liauw A; Wang Z; Emmett G; Wacker DA; Welch PK; Covington M; Stowell NC; Wadman EA; Das AM; Davies P; Yeleswaram S; Graden DM; Solomon KA; Newton RC; Trainor GL; Decicco CP; Ko SS
    J Med Chem; 2005 Mar; 48(6):2194-211. PubMed ID: 15771462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists.
    Pasternak A; Marino D; Vicario PP; Ayala JM; Cascierri MA; Parsons W; Mills SG; Maccoss M; Yang L
    J Med Chem; 2006 Aug; 49(16):4801-4. PubMed ID: 16884289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines.
    Yokoyama K; Ishikawa N; Igarashi S; Kawano N; Masuda N; Hamaguchi W; Yamasaki S; Koganemaru Y; Hattori K; Miyazaki T; Ogino S; Matsumoto Y; Takeuchi M; Ohta M
    Bioorg Med Chem; 2009 Jan; 17(1):64-73. PubMed ID: 19081254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single-step enrichment of Th2 lymphocytes using CCR4 microbeads.
    Pappas J; Quan N; Ghildyal N
    Immunol Lett; 2006 Jan; 102(1):110-4. PubMed ID: 16143405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists.
    Xie YF; Lake K; Ligsay K; Komandla M; Sircar I; Nagarajan G; Li J; Xu K; Parise J; Schneider L; Huang D; Liu J; Dines K; Sakurai N; Barbosa M; Jack R
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3367-72. PubMed ID: 17446072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay.
    Yagi H; Seo N; Ohshima A; Itoh T; Itoh N; Horibe T; Yoshinari Y; Takigawa M; Hashizume H
    Am J Surg Pathol; 2006 Sep; 30(9):1111-9. PubMed ID: 16931956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma.
    Ishida T; Iida S; Akatsuka Y; Ishii T; Miyazaki M; Komatsu H; Inagaki H; Okada N; Fujita T; Shitara K; Akinaga S; Takahashi T; Utsunomiya A; Ueda R
    Clin Cancer Res; 2004 Nov; 10(22):7529-39. PubMed ID: 15569983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists.
    Batt DG; Houghton GC; Roderick J; Santella JB; Wacker DA; Welch PK; Orlovsky YI; Wadman EA; Trzaskos JM; Davies P; Decicco CP; Carter PH
    Bioorg Med Chem Lett; 2005 Feb; 15(3):787-91. PubMed ID: 15664858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blockade of CCR4 in a humanized model of asthma reveals a critical role for DC-derived CCL17 and CCL22 in attracting Th2 cells and inducing airway inflammation.
    Perros F; Hoogsteden HC; Coyle AJ; Lambrecht BN; Hammad H
    Allergy; 2009 Jul; 64(7):995-1002. PubMed ID: 19630858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent small molecule CCR1 antagonists.
    Kath JC; Brissette WH; Brown MF; Conklyn M; DiRico AP; Dorff P; Gladue RP; Lillie BM; Lira PD; Mairs EN; Martin WH; McElroy EB; McGlynn MA; Paradis TJ; Poss CS; Stock IA; Tylaska LA; Zheng D
    Bioorg Med Chem Lett; 2004 May; 14(9):2169-73. PubMed ID: 15081002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3.
    Johnson M; Li AR; Liu J; Fu Z; Zhu L; Miao S; Wang X; Xu Q; Huang A; Marcus A; Xu F; Ebsworth K; Sablan E; Danao J; Kumer J; Dairaghi D; Lawrence C; Sullivan T; Tonn G; Schall T; Collins T; Medina J
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3339-43. PubMed ID: 17448658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitory effect of the new orally active CCR4 antagonist K327 on CCR4+CD4+ T cell migration into the lung of mice with ovalbumin-induced lung allergic inflammation.
    Sato T; Komai M; Iwase M; Kobayashi K; Tahara H; Ohshima E; Arai H; Miki I
    Pharmacology; 2009; 84(3):171-82. PubMed ID: 19713720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of chemokine receptors CXCR3 and CCR4 in lymphocytes of idiopathic nonspecific interstitial pneumonia.
    Yoshinouchi T; Naniwa T; Shimizu S; Ohtsuki Y; Fujita J; Sato S; Eimoto T; Ueda R
    Respir Med; 2007 Jun; 101(6):1258-64. PubMed ID: 17137778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.